Digital transformation is the most anticipated future of biopharma and healthcare. The medical community acknowledges the importance of digital health, but the cultural shift we expect is still nowhere near. The first step is to get to know what is happening in detail. To do just that, let’s dive into the emerging factors in the biopharma changing the future of the industry:
Digital health makes it possible for patients to take their health into their own hands. It is argued that patients’ opinions should be given equal importance in hospitals, pharmacies, and pharma companies. Their experience with the products of companies is helpful for research and development. The production of new medications will become easier if the requirements of patients are known. The help of patients can bring us a step closer to the futuristic health program.
The future of the pharma industry and healthcare does not revolve around manufacturing pills only. The accommodation of new approaches in technology has opened new doors for the biopharma industry. Some non-clinical solutions in the form of support groups can boost outcomes and help the entire health system. Patients receive more than just medications in this setting, and the pharma companies can use the data and feedback. They also win customer loyalty if they do it right. Reasonable non-clinical solutions are hard to come by. The best one yet has been the MySugr app that encouraged people with diabetes to keep their glucose levels in check.
The advancement in technology has opened a door for better clinical trial supplies and techniques. For example, In Silico, trials are conducted through computer simulation and bypass animal testing. According to research, silico practices replicate human clinical research, which is an efficient method.
Virtual reality therapies in the case of stress management and pain reduction have proved to be quite valuable. In the coming years, pharma industries, instead of making more painkillers, will consider stepping into the virtual reality field and developing newer techniques for healthcare. Brennan Spiegel and his team are experimenting with biotechnology, and they believe that the future is Virtual reality pharmacies with the doctors recommending appropriate virtual reality therapies.
Pharmacogenomics is the study of variability in drug response due to genetic code. All medications do not have the same effects on every individual, depending on their genetic makeup. The knowledge of pharmacogenomics can generate precision drugs (an emerging approach for disease treatment and prevention that considers individual variability in genes, environment, and lifestyle for each person), a step in creating personalized and targeted medication.
3D printing is churning the world of technology. From a group that printed a miniature kidney to new methods that can print heart-specific tissues, 3D printing is the way to go. It is speculated that pharma industries will be printing medications through the 3D printers with accuracy in the following decade.
There is a consensus in the pharma industry that the regulations for drugs are obsolete. Regulatory industries are conventional and are not ready to accept digital health. With increasing social media and technology influence, medicines regulators need to move fast, or they will become irrelevant.